Company / Revenue
NovaBay Pharmaceuticals, Inc. Revenue History
FY2015-FY2017 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$18.2M
FY2017
5-year range
-
FY2015-FY2017
Trend
+53.2%
vs FY2016
Sector context
#130 of 153
Health Care
What the data says
NovaBay Pharmaceuticals, Inc.'s revenue of $18M is lower than 85% of companies in the Health Care sector (FY2017). Improved from $4M to $18M over the past 2 years.
Based on SEC 10-K filings.
$18M in FY2017.
Improved from $4M to $18M over the past 2 years.
Health Care sector context is included.
Revenue over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 153This company $18.2M Sector average $4.5B
▼
-99.6% below sector average
Key checks
Key Insights
- In FY2017, revenue increased 53.2% year-over-year.
- Ranks #130 out of 153 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.51 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | $18.2M | +53.2% |
| FY2016 | $11.9M | +171.6% |
| FY2015 | $4.4M | +1084.1% |
As of FY2017 · SEC 10-K · Updated Feb 28, 2026